<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530685</url>
  </required_header>
  <id_info>
    <org_study_id>PILEJE-Glyca-0910</org_study_id>
    <nct_id>NCT01530685</nct_id>
  </id_info>
  <brief_title>Gycabiane and Glycemic Control of Prediabetic Subjects</brief_title>
  <official_title>Effect of Glycabiane, a Dietary Supplement, on Glycemic Control of Prediabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PiLeJe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larena SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of supplementation Glycabiane, a dietary&#xD;
      supplement, on glycemic control of overweight prediabetic subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cinnamon's effects on blood glucose have been the subject of many clinical and animal&#xD;
      studies; however, the issue of cinnamon intake's effect on fasting blood glucose (FBG) in&#xD;
      people with prediabetes still remains unclear.&#xD;
&#xD;
      The main purpose of this study is to examine the effects of supplementation with Glycabiane,&#xD;
      a dietary supplement rich in cinnamon extract, on fast blood glucose of overweight&#xD;
      prediabetic subjects in a randomized, placebo-controlled, clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2011</start_date>
  <completion_date type="Actual">September 25, 2012</completion_date>
  <primary_completion_date type="Actual">September 25, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fast Blood Glucose</measure>
    <time_frame>4 months</time_frame>
    <description>Fast blood glucose will be measured before and after 4 months of supplementation and after 2 months of wash-out</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Glycabiane, gelule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glycabiane</intervention_name>
    <description>2 gelule per day for 4 months</description>
    <arm_group_label>Glycabiane, gelule</arm_group_label>
    <other_name>Dietary supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 gelules per day for 4 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female from 25 to 65 years old&#xD;
&#xD;
          -  1.0g/L ≤ fast blood glucose &lt; 1.26g/L&#xD;
&#xD;
          -  overweight (IMC &gt; 25)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  thyroid disease&#xD;
&#xD;
          -  hypogonadism&#xD;
&#xD;
          -  History of musculoskeletal, autoimmune or neurological disease&#xD;
&#xD;
          -  Treatment against thyroid disease, hypoglycemia, hypertension, or anti-coagulant&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine Clément, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM U872</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Pitié Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cinnamon</keyword>
  <keyword>chromium</keyword>
  <keyword>prediabete</keyword>
  <keyword>overweight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

